Introduction
============

Breast cancer is a common type of malignancy in the world and a major cause of mortality in females between 30 and 59 years of age ([@b1-ol-0-0-7029]). Breast cancer is a heterogeneous disease in terms of histology, pathology, and genetic and molecular profiles ([@b2-ol-0-0-7029]). Despite diagnostic and therapeutic advances, breast cancer patients still often exhibit relapse or metastasis subsequent to therapy ([@b3-ol-0-0-7029]).

Tumors are morphologically heterogeneous, composed of undifferentiated and differentiated cells ([@b4-ol-0-0-7029]). Cancer stem cells (CSCs) have been identified as a subpopulation within the tumor possessing the ability to self-renew and differentiate into non-tumorigenic cell populations that constitute the bulk of the tumor ([@b5-ol-0-0-7029]). CSCs have been associated with tumor initiation, therapy resistance and tumor recurrence. CSCs are a major problem for cancer therapy, and the elimination of CSCs is required for an effective treatment ([@b6-ol-0-0-7029]). The presence of CSC population in breast cancer has been demonstrated in several studies ([@b7-ol-0-0-7029],[@b8-ol-0-0-7029]). Breast cancer stem cells (BCSCs) were first isolated by Al-Hajj *et al* ([@b9-ol-0-0-7029]) in 2003 from the pleural effusions of a patient. Specific cell surface markers and biomarkers are used to identify and isolate BCSCs. The adhesion molecule cluster of differentiation (CD) 44 is a multifunctional cell surface transmembrane glycoprotein that serves a role in cell adhesion, proliferation, differentiation, motility and migration ([@b10-ol-0-0-7029]). In breast cancer, CD44^+^/CD24^−^ expression was demonstrated as prospective phenotype to isolate BCSCs. Al-Hajj *et al* ([@b9-ol-0-0-7029]) reported that breast cancer cells exhibiting an increased expression of CD44^+^/CD24^−^ were able to form tumors when injected into immunodeficient mice.

Cyclin-dependent kinases (CDKs) serve an essential role in the control of the cell cycle, and are associated with cytoskeletal dynamics, epigenetic regulation, controlling stem cell self-renewal, regulating metabolism, cell migration, regulation of transcription, DNA damage, and genomic and chromosomal instability ([@b11-ol-0-0-7029]). The dysregulation of CDK expression contributes to the loss of normal cell cycle control, which leads to the formation and progression of cancer ([@b12-ol-0-0-7029]). Therefore, the inhibition of CDKs by small-molecule CDK inhibitors may be an effective treatment of cancer. The dysregulation of cyclin D and the CDK pathway in cancer cells may inhibit senescence and promote cellular proliferation ([@b13-ol-0-0-7029]). By using various different mechanisms, malignant cells may increase cyclin D-dependent activity. The cyclin D-CDK4/6-retinoblastoma pathway controls the cell cycle restriction point, and is commonly dysregulated in breast cancer, making it a possible target for anticancer therapy ([@b14-ol-0-0-7029]).

Flavopiridol is a semisynthetic flavonoid that was the first CDK inhibitor used in clinical trials ([@b15-ol-0-0-7029]). Flavopiridol exhibits an antitumor effect against a variety of tumor types, including several solid tumors, through cytostatic activity, and induces cell cycle arrest and apoptosis ([@b16-ol-0-0-7029]). This flavonoid is a promising anticancer drug that is undergoing phase I and II clinical trials for chronic myeloid leukemia and pancreatic cancer ([@b17-ol-0-0-7029],[@b18-ol-0-0-7029]). Our previous study demonstrated that flavopiridol induced growth inhibition and apoptosis in CD133^+^/CD44^+^ prostate CSCs ([@b19-ol-0-0-7029]).

BCSCs have been proposed to be responsible for numerous properties of breast cancer such as resistance, metastatic properties and recurrence ([@b20-ol-0-0-7029]). Conventional anticancer therapies may kill the majority of the cancer cells, but CSCs are not affected by these therapies ([@b21-ol-0-0-7029]). For a more effective treatment of breast cancer, it may be necessary to target CSCs. Genome-wide gene expression profiling based on microarray analysis is a powerful tool to elucidate the possible mechanisms of cancer drugs. The present study aimed to investigate the cytotoxic effects and underlying mechanism of action of flavopiridol against human breast CSCs.

Materials and methods
=====================

### Cell culture conditions and reagents

Human breast cancer MCF7 cells were obtained from Interlab Cell Line Collection (Genova, Italy) and were grown in monolayer cell culture in RPMI 1640 culture medium (Lonza Group AG, Basel, Switzerland) containing 10% heat-inactivated fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1% penicillin and 1% streptomycin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The cells were cultured in 25-cm^2^ polystyrene flasks (Corning Life Sciences, Corning, NY, USA) and incubated for 48 h at 37°C in a humidified atmosphere of 5% CO~2~. Flavopiridol (Sigma-Aldrich; Merck KGaA) was prepared as 10 mM stock solution in dimethyl sulfoxide (DMSO), and the final volume of DMSO did not exceed 0.1% of the total incubation volume and was not cytotoxic to the tumor cells at these concentrations (data not shown).

### Fluorescence-activated cell sorting (FACS)

To sort the CSCs subpopulations in the human breast cancer MCF7 cell line, the antibodies of expressed surface markers CD44^+^/CD24^−^, anti-CD44 conjugated to fluorescein isothiocyanate (10 µl/10^6^ cell; FITC; cat. no. 555478; BD Biosciences, Franklin Lakes, NJ, USA) and anti-CD24 conjugated to phycoerythrin (10 µl/10^6^ cell; PE; clone 32D12; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) were used. The MCF7 cells were seeded and grown to 80% confluence. The cells were detached using a non-enzymatic cell dissociation solution (Sigma-Aldrich; Merck KGaA) and resuspended in RPMI 1640 culture medium. A total of \~5×10^4^ cells were incubated with anti-CD44-fluorescein isothiocyanate (FITC; clone G44 26; BD Biosciences, Franklin Lakes, NJ, USA) and anti-CD24-phycoerythrin (PE; clone 32D12; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) in FACS stain buffer (cat. no. 554657; BD Pharmingen, Franklin Lakes, NJ, USA) for 15 min at 4°C. After 15 min, the cells were washed with the above FACS wash buffer and resuspended in FACS stain buffer (cat. no 554657, BD Pharmingen, Franklin Lakes, NJ, USA) to a density of 10^7^ cells/ml. The cells were sorted into a CD44^+^/CD24^−^ population (sorted cells) using a FACSAria flow cytometer (BD Biosciences).

### Analysis of cell viability

The viability of the cells following treatment was determined using the Muse^®^ Count & Viability kit (Muse Cell Analyzer; EMD Millipore, Billerica, MA, USA) according to the protocol of the manufacturer. The cells were seeded in triplicate in 6-well plates at a density of 1×10^4^ cells/well. Subsequent to a 24-h incubation, the cells were exposed to 500, 750 and 1,000 nM flavopiridol. The plates were then incubated at 37°C in a 5% CO~2~ incubator for 24, 48 and 72 h. Subsequent to incubation, all cells were collected and diluted with PBS. In total, 50 µl of the cell suspension was then added to 450 µl Muse^®^ Count & Viability reagent (dilution, 10X), incubated for 5 min at room temperature and analyzed using the Muse Cell Analyzer. Data were presented as proportional viability (%) by comparing the treated group with the untreated cells.

### RNA isolation and microarray analysis

The BCSCs were treated with a dose of flavopiridol equivalent to its half maximal inhibitory concentration (IC~50~). Total RNA was extracted from the treated and untreated cells using the RNeasy Mini kit (Qiagen, Inc., Valencia, CA, USA) according to the protocol of the manufacturer. Biotin-labeled RNA samples for hybridization on Illumina Human HT-12 v4 Expression BeadChip (Illumina, Inc., San Diego, CA, USA) were prepared according to the recommended sample labeling procedure of Illumina, Inc. A total of 250 ng total RNA was used for cDNA synthesis, followed by an amplification/labeling step to synthesize biotin-labeled cRNA. The quality of the cRNA was controlled using the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). Hybridization was performed at 58°C in GEX-HCB buffer (Illumina, Inc.) at a concentration of 150 ng cRNA/µl. The BeadChips were subsequently washed, blocked and conjugated with cyanine 3-streptavidin (Thermo Fisher Scientific, Inc.). The microarrays were scanned in the iScan System (Illumina, Inc.). The obtained amplification data (fold-changes in the quantification cycle values of all the genes) were processed in Agilent GeneSpring Data Analysing Software (Agilent Technologies, Inc.) and \>2 fold-change was used for filtering criteria.

### Statistical analysis

The statistical software package SPSS version 20.0 for Windows (IBM Corp., Armonk, NY USA) was used for all statistical analysis. All experiments were performed independently three times. Statistical analysis was tested by one-way analysis of variance, followed by Tukey\'s or Dunnett\'s post hoc tests. All data are presented as mean ± standard deviation from 3 independent experiments. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Sorting breast cancer MCF7 cells and purity of the CD44^+^/CD24^−^ sorted subpopulations

Human breast cancer MCF7 cells were separated with FACS, yielding a CD44^+^/CD24^−^ population ([Fig. 1](#f1-ol-0-0-7029){ref-type="fig"}). The present study obtained MCF7 CSC and non-CSC subpopulations. According to the results, the mean percentage of MCF7 CSCs and non-CSCs were 1.6 and 98.4%, respectively. The purity of the CSCs samples was tested with anti-CD44 and anti-CD24 antibodies. The sorting rate analysis and purity of the cells were evaluated sequentially, and the rate was 96.7±5.4% for the sorted cells. To confirm the flow cytometry analyses, the cells were re-evaluated following sorting, and the analyses were repeated subsequent to one passage. The results revealed that the cell purity following sorting was \>90%.

### Increasing cytotoxicity of CD44^+^/CD24^−^ BCSCs with flavopiridol

Cytotoxicity assays were performed to determine the therapeutic effect of flavopiridol. MCF7 CSCs were exposed to 100--1,000 nM flavopiridol for 24, 48 and 72 h, and the percentage of viable cells in the samples was determined by a cell viability assay. Flavopiridol reduced the cell viability of CSCs in a time- and concentration-dependent manner ([Fig. 2A-C](#f2-ol-0-0-7029){ref-type="fig"}). According to the data, there were no significant decreases in cell viability at the low doses (100 and 300 nM) of flavopiridol treatment for 24 h compared with that of the untreated cells (P=0.642). After 48 h of treatment, flavopiridol significantly reduced the cell viability of BCSCs at 500, 750 and 1,000 nM compared with that of the untreated cells (P=0.000). After 72 h of treatment with flavopiridol, the IC~50~ was calculated as 500 nM.

### Microarray analysis for the identification of differentially expressed genes in MCF7 CD44^+^/CD24^−^ cells treated with flavopiridol

To analyze the molecular mechanisms underlying the anticancer effect of flavopiridol in BCSCs, the MCF7 CD44^+^/CD24^−^ cells were treated with 500 nM flavopiridol for 72 h. To identify flavopiridol-regulated genes and determine the possible mechanism underlying the differential role of flavopiridol on the growth of MCF7 CD44^+^/CD24^−^ cells, global gene expression profiling was undertaken following treatment with flavopiridol using the Illumina Human HT-12 v4 Expression BeadChip. According to the results of microarray analysis, 65 genes were identified as significantly affected subsequent to treatment with flavopiridol, since the expression of 57 genes decreased and the expression of 8 genes increased compared with that in untreated cells at 72 h ([Table I](#tI-ol-0-0-7029){ref-type="table"}).

To investigate the mechanism involved in the flavopiridol-induced antiproliferative effect on MCF7 CD44^+^/CD24^−^ CSCs, pathway analysis was performed using the WikiPathways database ([www.wikipathways.org](www.wikipathways.org)). Specifically, these pathways are involved in the translation pathway, ribosome biogenesis, oxidative phosphorylation, the electron transport chain pathway, carbon metabolism, mammary gland development, protein modification and the cell cycle ([Fig. 3A and B](#f3-ol-0-0-7029){ref-type="fig"}).

Discussion
==========

BCSCs have been identified as subpopulations of cells within breast tumors that possess tumor-initiating potential in addition to the ability to self-renew and differentiate into a diverse range of progeny cells that make up the tumor ([@b22-ol-0-0-7029]) These cells are resistant to traditional therapies against cancer, including chemotherapy and radiation therapy ([@b5-ol-0-0-7029]). Although treatments associated with cancer therapy kill the majority of tumor cells, CSCs are not killed ([@b23-ol-0-0-7029]). Therefore, a more effective strategy for the treatment of breast cancer may target CSCs. The present study investigated the effect and underlying mechanism of flavopiridol on BCSCs with respect to antitumor properties. The results demonstrated that flavopiridol dose-dependently induced the growth inhibition of BCSCs.

To isolate populations of BCSCs within tumors, the phenotypic definition of a CSC must first be established. CSCs have been identified using cell surface markers in the majority of cancer types. The present study isolated BCSCs based on the CD44^+^/CD24^−^ phenotype from the breast cancer MCF7 cell line. Al-Hajj *et al* ([@b9-ol-0-0-7029]) revealed that breast cancer tumorigenic cells exhibit a CD44^+^/CD24^−^/low phenotype. Several studies have used the CD44^+^/CD24^−^and/or the aldehyde dehydrogenase (ALDH)^+^ phenotype for BCSC isolation ([@b9-ol-0-0-7029],[@b24-ol-0-0-7029]). Ginestier *et al* ([@b25-ol-0-0-7029]) isolated stem-like cells from primary breast xenografts using CD44^+^/CD24^−^ and ALDH activity, revealing that these cells displayed the greatest tumor-initiating capacity, generating tumors in non-obese diabetic/severe combined immunodeficiency mice from as little as 20 cells.

Cyclins and CDK inhibitors are involved in cell morphogenesis, adhesion, migration, DNA repair, transcription, cytoskeleton dynamics and cell motility. Flavopiridol is the first CDK inhibitor that exhibits an antitumor effect against a variety of tumor types in several solid tumors ([@b26-ol-0-0-7029]) The results of the present study revealed that flavopiridol reduced the level of cell viability of BCSCs in a dose- and time-dependent manner, and that flavopiridol appears to possess multiple targets within tumor cells. The number of publications involving the effect of flavopiridol on CSC is quite limited. Soner *et al* ([@b19-ol-0-0-7029]) demonstrated that flavopiridol induced growth inhibition and apoptosis by the upregulation of p53 and caspases 3 and 8 in CD133^+^/CD44^+^ prostrate CSCs.

The translation and ribosome biogenesis pathways serve important roles in numerous cellular processes and are more active in cancer cells compared with those in normal cells. The inhibition of translation and ribosome biogenesis have been reported to be associated with alterations in the cell cycle and the regulation of cell growth ([@b27-ol-0-0-7029]). The present study demonstrated that flavopiridol induced the downregulation of translation and ribosome biogenesis genes in CSCs. According to previous studies, flavopiridol induced G1/S-phase cell cycle arrest ([@b28-ol-0-0-7029],[@b29-ol-0-0-7029]). The mechanism of flavopiridol on the cell cycle may be associated with ribosome biogenesis. Cancer cells have been suggested to exhibit a higher rate of ribosome biogenesis compared with that in normal cells. Changes of proto-oncogenes and tumor-suppressor genes activate the mechanisms that stimulate cell growth and proliferation, and initiate certain pathways that enhance ribosome biogenesis ([@b30-ol-0-0-7029],[@b31-ol-0-0-7029]). Derenzini *et al* ([@b32-ol-0-0-7029]) demonstrated that the inhibition of ribosomal RNA synthesis caused an accelerated or delayed G1/S-phase progression in rat hepatoma cells.

The present study demonstrated the effects of flavopiridol on BCSCs, suggesting that flavopiridol induced growth inhibition in CD44^+^/CD24^−^ BCSCs and inhibited the translation and ribosome biogenesis pathways. Flavopiridol is one of the most promising chemotherapy drug candidates for the treatment of cancer. However, the data on the effects of flavopiridol on cancer remain limited. An increased understanding of the mechanisms responsible for the effects of the drug is required to improve novel therapeutic strategies for breast cancer. Combination drug therapies targeting CSCs may be an effective method to prevent relapse and resistance in cancer therapies.

![Flow cytometry analysis of CD44^+^/CD24^−^ subpopulations in MCF7 cell lines. CD44^+^/CD24^−^ populations are presented in P1. CD, cluster of differentiation; SSC-A, side scatter area; FSC-A, forward scatter area; FITC-A, fluorescein isothiocyanate area; PE-A, phycoerythrin area.](ol-14-06-6433-g00){#f1-ol-0-0-7029}

![Representative cell viability profile of CD44^+^/CD24^−^ breast cancer stem cells non-treated or treated with 100, 300, 500, 750 and 1,000 nM flavopiridol subsequent to (A) 24, (B) 48 and (C) 72 h of incubation. Each concentration was studied as three replicates.](ol-14-06-6433-g01){#f2-ol-0-0-7029}

![(A) Heat map showing the normalized expression of differentially regulated genes, filtering criteria \>2-fold change in flavopiridol-treated and untreated MCF7 CD44^+^/CD24^−^ cancer stem cells. Red color indicates high expression, while green color indicates expression. (B) Pie chart representing the proportion of genes associated with various pathways. CD, cluster of differentiation.](ol-14-06-6433-g02){#f3-ol-0-0-7029}

###### 

Changes in the expression of upregulated and downregulated genes following treatment with flavopiridol.

  A, Translation pathway and ribosome biogenesis pathway                                                                                                               
  ----------------------------------------------------------------------- ------------ -------------------------------------------------------------- ---------------- ----------------------------------------------------------------------
  4920193                                                                 RPL27A       −2.7026234                                                     Down             RPL27a
  6060356                                                                 RPL13A       −2.1516730                                                     Down             RPL13a
  3360228                                                                 RPS20        −2.0229893                                                     Down             RPS20
  5290082                                                                 RPLP1        −2.1037197                                                     Down             RiP, large, P1
  1710369                                                                 RPL3         −2.5006313                                                     Down             RPL3, transcript variant 2
  620754                                                                  RPS5         −2.3889322                                                     Down             RPS5
  7040095                                                                 RPL17        −2.0128388                                                     Down             RPL17, transcript variant 2
  990273                                                                  RPL37A       −2.2212677                                                     Down             RP L37a
  3060477                                                                 RPL8         −2.4217634                                                     Down             RPL8, transcript variant 2
  3610241                                                                 RPL19        −3.2778310                                                     Down             RPL19
  3800332                                                                 RPS25        −2.3831854                                                     Down             RPS25
  5260682                                                                 RPS14        −2.5092149                                                     Down             RPS14, transcript variant 2
  5220037                                                                 RPS2         −3.9913297                                                     Down             RPS2
  6960181                                                                 RPS12        −2.9727620                                                     Down             RPS12
  7510482                                                                 RPS4X        −2.1651378                                                     Down             RPS4, X-linked
  20021                                                                   RPS15        −2.4493800                                                     Down             RPS15
  5560349                                                                 RPS11        −2.6253710                                                     Down             RRPS11
  5890730                                                                 RPS26L       −2.8872151                                                     Down             Predicted: *Homo sapiens* 40S RPS26-like
  510195                                                                  RPL27        −2.4229383                                                     Down             RPL27
  840647                                                                  RPL36        −2.7411752                                                     Down             RPL36, transcript variant 1
  4250445                                                                 RPL4         −2.0928760                                                     Down             RPL4
  6250097                                                                 RPS9         −2.3448272                                                     Down             RPS9
  1410537                                                                 RPSA         −2.1424713                                                     Down             RPSA, transcript variant 1
  6270546                                                                 RPS6         −2.3560820                                                     Down             RPS6
  6590377                                                                 RPS26        −2.1171474                                                     Down             RPS26
  4250445                                                                 RPL4         −2.0012200                                                     Down             RPL4
  3610309                                                                 LOC653881    −2.6014566                                                     Down             Predicted: Similar to RPL3
  2490450                                                                 LOC91561     −2.2661705                                                     Down             Predicted: Similar to RPS2, transcript variant 3
  3440670                                                                 LOC402251    −2.3879724                                                     Down             Predicted: Similar to eukaryotic translation elongation factor 1 α 2
  4060446                                                                 LOC649150    −3.2092447                                                     Down             Predicted: Similar to eukaryotic translation elongation factor 1 α 2
  1440398                                                                 LOC644511    −2.2366867                                                     Down             Predicted: Similar to RPL13a, transcript variant 1
  1570491                                                                 LOC648000    −2.3058624                                                     Down             Predicted: Similar to 60S RPL7, transcript variant 1
  2320494                                                                 LOC653314    −3.1144562                                                     Down             *Homo sapiens* similar to RPL19
  6280021                                                                 LOC441876    −2.8330393                                                     Down             Predicted: Similar to 40S RPS16,
  870593                                                                  LOC285053    −2.3860030                                                     Down             Predicted: Similar to RPL18a, transcript variant 1
  5720747                                                                 LOC441775    −2.6068625                                                     Down             Predicted: Similar to 60S RPL18
  2190546                                                                 LOC388654    −2.2629400                                                     Down             Predicted: Similar to laminin receptor 1 (RPSA)
  5720747                                                                 LOC441775    −2.6068625                                                     Down             Predicted: Similar to 60S RPL18
  6330373                                                                 EEF1B2       −2.3026142                                                     Down             Eukaryotic translation elongation factor 1 β 2, transcript variant 1
  3850121                                                                 EEF1A1       −3.1777650                                                     Down             Eukaryotic translation elongation factor 1 α 1
                                                                                                                                                                       
  **B, Oxidative phosphorylation and electron transport chain pathway**                                                                                                
                                                                                                                                                                       
  3850110                                                                 COX6A1       −2.1455740                                                     Down             Cytochrome *c* oxidase subunit Vıa polypeptide 1
  4490259                                                                 COX8A        −2.9969997                                                     Down             Cytochrome *c* oxidase subunit 8A (ubiquitous)
                                                                                                                                                                       
  **C, Carbon metabolism**                                                                                                                                             
                                                                                                                                                                       
  2760358                                                                 NME1-2       −2.3299380                                                     Down             NME1-NME2 readthrough
  1940360                                                                 TPI1         −2.8388138                                                     Down             Triosephosphate isomerase 1
  6590253                                                                 ALDOA        −2.1273860                                                     Down             ALDOA
  6520128                                                                 GPX4         −2.1577030                                                     Down             Glutathione peroxidase
                                                                                                                                                                       
  **D, Mammary gland development pathway**                                                                                                                             
                                                                                                                                                                       
  5860138                                                                 RIPK4        −2.1919790                                                     Down             Receptor-interacting serine-threonine kinase 4
                                                                                                                                                                       
  **E, G protein-mediated signaling pathway via Gα12/Gα13 family**                                                                                                     
                                                                                                                                                                       
  2850402                                                                 PFN1         −2.4898353                                                     Down             Profilin 1
                                                                                                                                                                       
  **F, Tumor necrosis factor-mediated signaling pathway**                                                                                                              
                                                                                                                                                                       
  670673                                                                  BCL2L1       −2.0002713                                                     Down             BCL2-like 1, nuclear gene encoding mitochondrial
                                                                                                                                                                       
  **G, Signaling pathway pertinent to immunity**                                                                                                                       
                                                                                                                                                                       
  1980594                                                                 FTHL8        −3.2119188                                                     Down             Ferritin, heavy polypeptide-like 8
  2970431                                                                 FTHL7        −4.2565985                                                     Down               FTHL7
                                                                                                                                                                       
  **H, Toll-like receptor signaling pathway**                                                                                                                          
                                                                                                                                                                       
  3840154                                                                 SPP1         −3.0712519                                                     Down             SPP1, transcript variant 1
                                                                                                                                                                       
  **I, Signaling by TGF-β receptor complex**                                                                                                                           
                                                                                                                                                                       
  1430239                                                                 UBC          −2.8056865                                                     Down             UBC
                                                                                                                                                                       
  **J, Regulatory and cell adhesion signaling pathways**                                                                                                               
                                                                                                                                                                       
  5570132                                                                 ACTB         −3.4210854                                                     Down             Actin, β
                                                                                                                                                                       
  **K, NRF2 pathway**                                                                                                                                                  
                                                                                                                                                                       
  4920767                                                                 FTL          −3.1391878                                                     Down             Ferritin, light polypeptide
                                                                                                                                                                       
  **L, Folate-alcohol and cancer pathway**                                                                                                                             
                                                                                                                                                                       
  6510754                                                                 ALDH1A1      −2.9203625                                                     Down             Aldehyde dehydrogenase 1 familyer A1
                                                                                                                                                                       
  **M, Cell adhesion signaling pathway**                                                                                                                               
                                                                                                                                                                       
  610437                                                                  CD24         2.9155455                                                      Up               CD24 molecule
                                                                                                                                                                       
  **N, Calcium/calcium-mediated signaling pathway**                                                                                                                    
                                                                                                                                                                       
  7100711                                                                 CALM2        2.7985630                                                      Up               Calmodulin 2 (phosphorylase kinase, delta)
                                                                                                                                                                       
  **O, Amino acid metabolism**                                                                                                                                         
                                                                                                                                                                       
  450161                                                                  FAHD1        2.1592160                                                      Up               Fumarylacetoacetate hydrolase domain containing 1
                                                                                                                                                                       
  **P, Protein modification pathway**                                                                                                                                  
                                                                                                                                                                       
  **Probe ID**                                                            **Symbol**   **Fold-change^[a](#tfn1-ol-0-0-7029){ref-type="table-fn"}^**   **Regulation**   **Definition**
                                                                                                                                                                       
  4590110                                                                 SEPT9        2.2080840                                                      Up               Septin 9
                                                                                                                                                                       
  **Q, Cell cycle**                                                                                                                                                    
                                                                                                                                                                       
  870491                                                                  BUB3         2.1889267                                                      Up               BUB3 budding uninhibited by benzimidazoles 3
                                                                                                                                                                       
  **R, Regulation of actin cytoskeleton**                                                                                                                              
                                                                                                                                                                       
  2760292                                                                 PPP1CC       2.6673288                                                      Up               Protein phosphatase 1, catalytic subunit
                                                                                                                                                                       
  **S, Vasopressin-regulated water reabsorption**                                                                                                                      
                                                                                                                                                                       
  4230520                                                                 DNCL1        2.0563870                                                      Up               Dynein, cytoplasmic, light polypeptide 1
                                                                                                                                                                       
  **T, Transport pathway**                                                                                                                                             
                                                                                                                                                                       
  1740136                                                                 SLC38A2      2.1263490                                                      Up               Solute carrier family 38, member 2

\>2 fold-change was considered to be significant (P\<0.05). NME, nucleoside diphosphate kinase; ALDOA, aldolase A, fructose-bisphosphate; BCL-2, B-cell lymphoma 2; RP, ribosomal protein; FTHL7, ferritin, heavy polypeptide-like 7; SPP1, secreted phosphoprotein 1; UBC, ubiquitin C; CD, cluster of differentiation; TGF, transforming growth factor; ACTB, actin, beta; FTL, ferritin, light polypeptide; ALDH1A1, aldehyde dehydrogenase 1 family, member A1; CD24, CD24 molecule; CALM2, calmodulin 2; FAHD1, fumarylacetoacetate hydrolase domain containing 1; BUB3, BUB3 budding uninhibited by benzimidazoles 3; PPP1CC, protein phosphatase 1, catalytic subunit; DNCL1, dynein, cytoplasmic, light polypeptide 1; SLC38A2, solute carrier family 38, member 2.
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